Nicholas Fidelman, MD

Professor
University Of California San Francisco, United States

Presentation(s):

• Yttrium-90 radioembolization with and without capecitabine for colorectal cancer liver metastases

  Sunday, March 30, 2025
  4:21 PM – 4:30 PM CT

• Randomized Embolization Trial for NeuroEndocrine Tumors (RETNET)

  Sunday, March 30, 2025
  3:54 PM – 4:03 PM CT

• Comparing Demographic Factors and Outcomes in Hepatocellular Carcinoma Treatment: Evaluation of Y90 Radioembolization versus Combined TACE plus MWA

  Monday, March 31, 2025
  3:00 PM – 3:09 PM CT

• Liver-directed therapy for metastatic neuroendocrine carcinoma and grade 3 well-differentiated neuroendocrine tumors

  Tuesday, April 1, 2025
  3:09 PM – 3:18 PM CT

• Associations between patterns of neuroendocrine liver metastatic burden and outcomes after liver-directed therapy, systemic chemotherapy and systemic radiotherapy.

  Tuesday, April 1, 2025
  3:36 PM – 3:45 PM CT